Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US8292141053
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BS2ZD1
SLP
Simulations Plus Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Health Information Services · THEMEFOLIO: $HLTH
NAME
Simulations Plus Inc
ISIN
US8292141053
TICKER
SLP
MIC
XNAS
REUTERS
SLP.OQ
BLOOMBERG
SLP US
Mi., 24.06.2026       Simulations Plus
US8292141053

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company’s financial ou...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Simulations Plus
US8292141053

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material informati...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Simulations Plus
US8292141053

The DJS Law Group announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inv...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Simulations Plus
US8292141053

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC. Under the terms of the proposed transaction, shareholders of Simulations will receive $18.50 in cash for each share of Si...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Simulations Plus
US8292141053

NEW YORK, June 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Simulations Plus
US8292141053

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or fai...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Simulations Plus
US8292141053

MILWAUKEE, June 16, 2026 /PRNewswire/ -- Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Altaris. Click here to learn how to join our investigation and obtain addi...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Simulations Plus
US8292141053

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Simulations Plus, Inc. (NASDAQ: SLP) to affiliates of Altaris, LLC for $18.50 per share.Halper Sadeh encourages Simulations Plus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-006...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it has entered into a definitive agreement to be acquired by affiliates of Altaris, LLC (“Altaris”), an investment firm with an exclusive focus on...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 16.06.2026       Simulations Plus
US8292141053

Instrument ID [26624958] (SD3 - US8292141053) suspended...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       Simulations Plus
US8292141053

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company’s financial ou...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       Simulations Plus
US8292141053

San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose mat...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 08.06.2026       Simulations Plus
US8292141053

SAN DIEGO, June 5, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material informatio...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 03.06.2026       Simulations Plus
US8292141053

San Diego, California--(Newsfile Corp. - June 3, 2026) - Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws after the Company reduced its fiscal 2025 revenue outlook, reported a significant impairment charge, and disclosed an auditor dispute involv...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2026       Simulations Plus
US8292141053

SAN DIEGO, June 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the   pharmaceutical, biotechn...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2026       Simulations Plus
US8292141053

Johnson Fistel, PLLP is investigating potential claims on behalf of Simulations Plus, Inc. (NASDAQ: SLP) investors concerning whether the Company or certain of its executive officers violated federal securities laws.The Simulations Plus investigation focuses on investor losses following the Company’s revised fiscal 2025 revenue outlook, reported im...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Simulations Plus
US8292141053

Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries. On June...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in M...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intens...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 21.04.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to servin...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) a...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug developmen...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Cli...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the i...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Heal...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 09.02.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 08.02.2026       Simulations Plus
US8292141053

NEW YORK, Feb. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from alleg...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Sa., 07.02.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - February 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Simulations Plus
US8292141053

NEW YORK, Feb. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from alleg...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences: BTIG 13th Annual MedTech, Digital Health, Life Scienc...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 01.02.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - February 1, 2026) - WHY:  Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Sa., 31.01.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - January 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 30.01.2026       Simulations Plus
US8292141053

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from alle...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 26.01.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - January 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 25.01.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - January 25, 2026) - WHY:Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the inv...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 23.01.2026       Simulations Plus
US8292141053

NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from alle...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - January 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to t...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug develop...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
So., 18.01.2026       Simulations Plus
US8292141053

New York, New York--(Newsfile Corp. - January 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the in...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. First Quarter 2026 Financial Highlights (as compared to first quarter 20...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026. The event will offer investors and analysts an in-depth look at the Company’s...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mi., 17.12.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Management will host a conference call that...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 16.12.2025       Simulations Plus
US8292141053

Das Instrument SD3 US8292141053 SIMULATIONS PLUS DL-,01 EQUITY hat seinen ersten Handelstag am 17.12.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N The instrument SD3 US8292141053 SIMULATIONS PLUS DL-,01 EQUITY has its first trading date on 17.12.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidanc...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Mo., 01.12.2025       Simulations Plus
US8292141053

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial...
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Fr., 28.11.2025       Simulations Plus
US8292141053

NEWTOWN, Pa., Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink
Do., 20.11.2025       Simulations Plus
US8292141053

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Simulations Plus
Charts & Research Termsheets Terminal
Permalink